LEE R BROCK MD
Prescription History 1063444792
Specialist in Fredericksburg, VA

NPI Status: Active since July 06, 2006

Contact Information

4304 LAFAYETTE BLVD
FREDERICKSBURG, VA
ZIP 22408
Phone: (540) 891-4444
Fax: (540) 891-9034

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LEE R BROCK MD, an active Specialist specialist practicing in Fredericksburg, VA. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 489 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 213 claims alone.


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 65
30-Day Fills 141.0
Days Supply 4,231
VA State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills125.5
Peer Average Days Supply3,611
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,918.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.29

State Avg Cost Per Claim

$42.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 52
30-Day Fills 115.2
Days Supply 3,454
VA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills117.4
Peer Average Days Supply3,501
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,252.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.08

State Avg Cost Per Claim

$31.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 64
30-Day Fills 129.6
Days Supply 3,888
VA State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills169.4
Peer Average Days Supply5,063
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,862.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.10

State Avg Cost Per Claim

$35.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 77
VA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills42.4
Peer Average Days Supply662
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.5% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.77

State Avg Cost Per Claim

$19.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 213
30-Day Fills 370.9
Days Supply 10,232
VA State Average Benchmarks
Peer Average Claims140.0
Peer Average 30-Day Fills274.2
Peer Average Days Supply7,923
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 52.1% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,468.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.28

State Avg Cost Per Claim

$21.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 42
30-Day Fills 46.5
Days Supply 815
VA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills40.7
Peer Average Days Supply652
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $673.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.03

State Avg Cost Per Claim

$14.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Rhopressa

Generic Formulation: Netarsudil MesylateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 46.5
Days Supply 1,361
VA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills74.9
Peer Average Days Supply2,125
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,708.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$623.10

State Avg Cost Per Claim

$502.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). This medication is thought to work by increasing the flow of fluid out of the eye. This helps lower pressure inside the eye. Lowering high pressure inside the eye can help prevent loss of vision or blindness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 38.7
Days Supply 1,130
VA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply711
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.9% more claims than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $197.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.88

State Avg Cost Per Claim

$409.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LEE R BROCK MD provides transparency into local medical care patterns within Fredericksburg, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.